Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Dianne Nguyen, Maria Paris, Lichen Teng, Jacob A Aelion, Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Dianne Nguyen, Maria Paris, Lichen Teng, Jacob A Aelion
Abstract
Objectives: The PALACE 4 trial evaluated apremilast monotherapy in patients with active PsA who were DMARD-naive.
Methods: Eligible patients were randomized (1:1:1) to placebo, apremilast 20 mg twice a day or apremilast 30 mg twice a day. At week 16 or 24, placebo patients were rerandomized to apremilast. Double-blind apremilast treatment continued to week 52, with extension up to 4 years. The primary endpoint was the proportion of patients achieving ⩾20% improvement in ACR response criteria (ACR20) at week 16; secondary endpoints included the mean change in the HAQ Disability Index (HAQ-DI) score at week 16.
Results: A total of 527 patients with mean disease duration of 3.4 years and high disease activity were randomized and received treatment. More apremilast patients achieved ACR20 response at week 16 [placebo, 15.9%; 20 mg, 28.0% (P = 0.0062); 30 mg, 30.7% (P = 0.0010)]. The mean HAQ-DI improvements were -0.17 (20 mg; P = 0.0008) and -0.21 (30 mg; P < 0.0001) vs 0.03 (placebo). Both apremilast doses showed significant ACR50 responses vs placebo at week 16 and improvements in secondary efficacy measures (swollen/tender joint counts) and psoriasis assessments, with sustained improvements through week 52. Common adverse events (AEs) over 52 weeks were diarrhoea, nausea, headache and upper respiratory tract infection; most events were mild or moderate. Serious AEs and AEs leading to discontinuation were comparable between groups. Laboratory abnormalities were infrequent and transient.
Conclusions: In DMARD-naive patients, apremilast monotherapy improved PsA signs/symptoms over 52 weeks and was generally well tolerated.
Trial registration: ClinicalTrials.gov (https://ichgcp.net/clinical-trials-registry/NCT01307423" title="See in ClinicalTrials.gov">NCT01307423.
Keywords: apremilast; monotherapy; phase III clinical trial; phosphodiesterase 4 inhibitor; psoriatic arthritis.
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Figures
References
- Gladman DD, Antoni C, Mease P, Clegg DO, Nash P.. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14–7.
- Singh JA, Strand V.. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol 2009;36:1012–20.
- Zhu TY, Tam LS, Leung YY. et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 2010;37:1214–20.
- Coates LC, Kavanaugh A, Mease PJ. et al. Group for research and assessment of psoriasis and psoriatic arthritis: treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol 2016;68:1060–71.
- Gossec L, Smolen JS, Ramiro S. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510.
- Fraser AD, van Kuijk AW, Westhovens R. et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859–64.
- Lebwohl MG, Bachelez H, Barker J. et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014;70:871–81.
- Coates LC, Moverley AR, McParland L. et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015;386:2489–98.
- Kavanaugh A, Mease PJ, Gomez-Reino JJ. et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020–6.
- Kavanaugh A, Mease PJ, Gomez-Reino JJ. et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol 2015;42:479–88.
- Cutolo M, Myerson GE, Fleischmann R. et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol 2016;43:1724–34.
- Edwards CJ, Blanco FJ, Crowley J. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016;75:1065–73.
- Kavanaugh A, Adebajo AO, Gladman DD. et al. Long-term (156-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1) [abstract 2843]. Arthritis Rheumatol 2015;67(Suppl 10):2843.
- Taylor W, Gladman D, Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
- Felson DT, Anderson JJ, Boers M. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
- El Miedany Y. Recent developments in management of psoriatic arthritis. Curr Rheumatol Rev 2005;1:9–19.
- Kwok T, Pope JE.. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 2010;37:1024–8.
- Mease PJ, Ganguly R, Wanke L, Yu E, Singh A.. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines [abstract SAT0015]. Ann Rheum Dis 2004;63(Suppl 1):391.
- Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A. et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.
- Schett G, Wollenhaupt J, Papp K. et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156–67.
- Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–2.
- Papp K, Cather JC, Rosoph L. et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380:738–46.
- Kingsley GH, Kowalczyk A, Taylor H. et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368–77.
- Nash P, Clegg DO.. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64(Suppl 2):ii74–7.
- Gottlieb AB, Mease PJ, Jackson JM. et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat 2006;17:279–87.
- Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M.. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009;23:683–91.
- Gossec L, Smolen JS, Gaujoux-Viala C. et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4–12.
- Menter A, Korman NJ, Elmets CA. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137–74.
- Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG.. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013;149:1180–5.
- Cutolo M, Myerson GE, Fleischmann RM. et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [abstract 815]. Arthritis Rheum 2013;65(10 Suppl):S346–7.
- Edwards CJ, Blanco FJ, Crowley J. et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [abstract 311]. Arthritis Rheum 2013;65(10 Suppl):S132.
Source: PubMed